Clinical Practices for Application by Eye Care Professionals Worldwide
SAN ANTONIO, November 8, 2018—A distinguished panel of global authorities in myopia management gathered this week in Texas, on the eve of the American Academy of Optometry (AAOptom) Annual Meeting, seeking ways to help eye care professionals better assess and manage the growing epidemic among children. The Myopia Management Expert Forum was conceived by CooperVision, which hosted the series of lectures, guided discussions and professional networking sessions.
“Much like we have seen at other major academic and clinical conferences over the past year, raising awareness of and more effectively addressing childhood myopia will be one of the most deliberated issues in San Antonio this week,” said Stuart Cockerill, Senior Director, Myopia Management at CooperVision. “By bringing some of the world’s foremost experts together in a unique educational setting, we made further progress in finding ways to deliver practical myopia management advice to eye care professionals (ECPs).”
After opening remarks by CooperVision Specialty EyeCare Division President J.C. Aragon, attendees heard from Paul Chamberlain, Director of Research Programs for CooperVision. He presented new four-year study data that showed the significant impact of a pioneering contact lens management approach to slowing myopia’s progression.
Conversation then turned to the impact of orthokeratology (ortho-k) in China. Maria Liu, OD, PhD, MPH, MBA, FAAO, the founder and Chief of the Myopia Control Clinic at the University of California, Berkeley, attributed promising outcomes in part to a trusted, collaborative myopia management approach between ophthalmologists and optometrists.
“A number of additional factors have emerged as critical to managing myopic children in China,” Dr. Liu remarked. “These include early consultation to parents of high-risk children, engaging in comprehensive discussions about individualized treatment and fee structures, and the need for manufacturers to help continue advancing myopia management practices through education.”
Additional discussion was led by Jan Roelof Polling, the noted myopia researcher at Erasmus Medical Centre, regarding encouraging experiences in the Netherlands, and by independent clinical trials consultant Robin Chalmers, OD, FAAO, on the safe use of contact lenses by children.
“Considering the worldwide growth of childhood myopia and its far-reaching impacts, discovering techniques to help ECPs embrace their roles as front-line heroes in confronting this scourge is essential. It’s an ongoing journey to help them understand when to begin and end treatment, how to cooperate with peers for coordinated care, and ways to draw attention to the issue as a public health crisis in their communities. What we learned in San Antonio lets us take another step forward,” said Stuart Cockerill, Senior Director, Myopia Management for CooperVision.
The prevalence of myopia is projected to increase from approximately two billion people worldwide in 2010 to almost five billion people in 20501, bringing with it near- and long-term health challenges. Not only does it create blurred vision, but also increases the likelihood of conditions later in life such as glaucoma, cataract, retinal detachment and myopic maculopathy if not addressed.
CooperVision’s leadership in myopia management will be visible throughout Academy ’18.
Mark Bullimore, MCOptom, PhD, FAAO, will present Myopia Control: From Evidence to Implementation on Thursday, November 8, at 9 a.m. in Hemisfair Ballroom C1. He is expected to incorporate three-year data from an ongoing CooperVision clinical trial is assessing a specially-designed, dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia. The lens is commercially available as CooperVision® MiSight® in select countries.2
On Friday, November 9, at 9 a.m. in the Cockrell Theatre, the International Myopia Institute will present its inaugural white paper report. CooperVision sponsors the Institute as part of its global support for the sector.
# # #
1Holden et al, Ophthalmology 2016.
2 MiSight® 1 day contact lenses are currently available for sale in Canada, the United Kingdom, France, Spain, Portugal, Netherlands, Germany, Austria, Switzerland, the Nordic Region, Singapore, Malaysia, Hong Kong, Australia and New Zealand. MiSight® is not approved in the United States.
About CooperVision
CooperVision, a unit of The Cooper Companies, Inc. (NYSE:COO), is one of the world’s leading manufacturers of soft contact lenses. The Company produces a full array of monthly, two-week and daily disposable contact lenses, all featuring advanced materials and optics. CooperVision has a strong heritage of solving the toughest vision challenges such as astigmatism and presbyopia; and offers the most complete collection of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com.
About The Cooper Companies
The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of families with its diversified portfolio of products and services focusing on women’s health, fertility and diagnostics. Headquartered in Pleasanton, Calif., Cooper has more than 12,000 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com.
--
Heather Kowalczyk, APR | Associate Vice President
McDougall Communications
121 Rue de Ville | Rochester, N.Y. 14618
585.330.4878 Direct | 585.434.2148 Desk
McDougallPR.com